Press Releases
-
Jun 18, 201911 Abstracts Featuring MiOXSYS have been Selected for Presentation at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology...Jun 12, 2019ENGLEWOOD, CO / ACCESSWIRE / June 12, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Natesto® has been featured on KPRC-TV, an NBC-affiliated television station in Houston, Texas, in a segment titled: 'Nasal spray for low testosterone preserves fertility.'...Jun 11, 2019ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual reconstitution. This will be effective after the US market opens on July 1, according to a preliminary ...Jun 4, 2019Initial Purchase by Beijing Dahua Sanxin Technology Development Co., Ltd. Represents First MiOXSYS Commercial Sale in China....May 21, 2019Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in the United KingdomENGLEWOOD, CO / ACCESSWIRE / May 21, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that MiOXSYS®, the company's first-in-class seminal oxidative stress test for the assessment of male infertility, is now available in the United Kingdom....May 14, 2019Company Posts Highest Ever Quarterly Revenue...May 7, 2019Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET...Apr 24, 2019Australian TGA Approval Decision Expected in Early 2020...Apr 16, 2019ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the formal appointment of Steven Boyd, Founder and Chief Investment Officer of Armistice Capital, to the Aytu BioScience board of directors. As previously announced in Decem...Mar 27, 2019Interim Results Demonstrated Preservation of Sperm Parameters After Six Months of Treatment with Nasally-Administered Natesto Testosterone Gel...